Vaxcyte (PCVX) Competitors $35.72 +0.08 (+0.22%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$35.67 -0.05 (-0.13%) As of 04:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PCVX vs. ITCI, GMAB, MRNA, RDY, VTRS, QGEN, ASND, BBIO, VRNA, and BPMCShould you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Vaxcyte vs. Its Competitors Intra-Cellular Therapies Genmab A/S Moderna Dr. Reddy's Laboratories Viatris Qiagen Ascendis Pharma A/S BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Intra-Cellular Therapies (NASDAQ:ITCI) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends. Do institutionals and insiders have more ownership in ITCI or PCVX? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor ITCI or PCVX? In the previous week, Vaxcyte had 4 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 4 mentions for Vaxcyte and 0 mentions for Intra-Cellular Therapies. Vaxcyte's average media sentiment score of 1.45 beat Intra-Cellular Therapies' score of 0.29 indicating that Vaxcyte is being referred to more favorably in the news media. Company Overall Sentiment Intra-Cellular Therapies Neutral Vaxcyte Positive Which has more risk & volatility, ITCI or PCVX? Intra-Cellular Therapies has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Do analysts prefer ITCI or PCVX? Intra-Cellular Therapies currently has a consensus price target of $109.70, indicating a potential downside of 16.81%. Vaxcyte has a consensus price target of $136.50, indicating a potential upside of 282.14%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Is ITCI or PCVX more profitable? Vaxcyte has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Vaxcyte N/A -17.12%-16.26% Which has better valuation & earnings, ITCI or PCVX? Intra-Cellular Therapies has higher revenue and earnings than Vaxcyte. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64VaxcyteN/AN/A-$463.93M-$3.99-8.95 SummaryVaxcyte beats Intra-Cellular Therapies on 11 of the 16 factors compared between the two stocks. Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCVX vs. The Competition Export to ExcelMetricVaxcyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.60B$2.93B$5.49B$9.45BDividend YieldN/A2.49%4.01%4.03%P/E Ratio-8.9520.5328.4719.90Price / SalesN/A266.81410.1985.18Price / CashN/A41.6635.9658.29Price / Book1.357.808.365.67Net Income-$463.93M-$55.10M$3.24B$258.18M7 Day Performance-2.32%4.62%3.13%2.81%1 Month Performance7.43%17.99%10.98%13.53%1 Year Performance-57.45%2.21%34.54%17.68% Vaxcyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCVXVaxcyte1.8576 of 5 stars$35.72+0.2%$136.50+282.1%-57.5%$4.60BN/A-8.95160Positive NewsITCIIntra-Cellular Therapies0.9972 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.1502 of 5 stars$21.46+0.3%$37.80+76.1%-21.6%$13.77B$3.12B12.192,682Positive NewsAnalyst DowngradeMRNAModerna4.2673 of 5 stars$32.87-2.3%$46.61+41.8%-73.3%$12.71B$3.24B-3.775,800Analyst ForecastRDYDr. Reddy's Laboratories3.1246 of 5 stars$14.58+0.4%$16.95+16.3%-9.9%$12.17B$325.54B22.0827,811Upcoming EarningsVTRSViatris2.6633 of 5 stars$9.14+0.2%$10.40+13.8%-20.8%$10.73B$14.74B-2.8832,000QGENQiagen3.7813 of 5 stars$48.25+0.3%$49.40+2.4%+20.5%$10.73B$1.98B120.985,765Positive NewsASNDAscendis Pharma A/S3.6199 of 5 stars$174.880.0%$223.07+27.6%+21.4%$10.69B$393.54M-27.851,017Positive NewsBBIOBridgeBio Pharma4.6068 of 5 stars$47.69+2.6%$61.20+28.3%+71.6%$9.06B$221.90M-13.51400Upcoming EarningsAnalyst ForecastVRNAVerona Pharma PLC American Depositary Share2.7207 of 5 stars$104.67-0.2%$109.00+4.1%+359.0%$8.91B$42.28M-52.3430High Trading VolumeBPMCBlueprint Medicines1.0977 of 5 stars$129.36+0.0%$128.25-0.9%N/A$8.35B$508.82M-52.37640Upcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Moderna Competitors Dr. Reddy's Laboratories Competitors Viatris Competitors Qiagen Competitors Ascendis Pharma A/S Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Blueprint Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCVX) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
